APDN, EvviVax Announce Publication of Positive Preclinical Data for Linear DNA™ Platform Approach to Cancer Immunotherapy
February 17th, 2022
All Categories
APDN in the News
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
Press Release
Uncategorized
Vaccines
Category: Press Release
APDN FQ1’22 Financial Results Feature Record Quarterly Revenues
February 10th, 2022
APDN Schedules FQ1’22 Financial Results Call and Webcast
February 3rd, 2022
Linea 1.0 COVID-19 Assay: Rapid Detection of Omicron Subvariant BA.2
January 28th, 2022
Request for FDA EUA for Linea™ 2.0 COVID-19 Assay, Linea™ Unsupervised At-Home Sample Collection Kit
January 21st, 2022
APDN Announces Continued Momentum in COVID-19 Testing Demand
January 18th, 2022
APDN Receives NYS Dept of Health Conditional Approval for Linea™ 2.0
January 4th, 2022
APDN, Isotech MoU to Leverage Isotopic Analysis for Cotton Authenticity
December 15th, 2021
APDN Reports 4th Quarter and Full Fiscal Year 2021 Financial Results
December 9th, 2021
